Journal of Endocrinological Investigation

, Volume 7, Issue 5, pp 525–527 | Cite as

Estrogenic treatment does not modify the TSH and PRL responses to domperidone and TRH in patients with tumoral hyperprolactinemia

  • E. Ghigo
  • G. Pogliano
  • C. Campagnoli
  • A. Bertagna
  • F. Camanni
  • F. Massara


To verify if the low estrogen regimen could condition the TSH hyperresponsivity and PRL hyporesponsivity to antidopaminergic drugs seen by us and others in patients bearing prolactinoma, the effect of ethynilestradiol treatment (50 μg/day/14 days) on TSH and PRL responses to domperidone in 6 women with tumoral hyperprolactinemia and hypoestrogenemia were studied. Estrogenic treatment was unable to modify the TSH and PRL responsiveness either to domperidone and TRH. These data do not support the hypothesis that hypoestrogenemia could cause the peculiar TSH and PRL pattern in response to antidopaminergic drugs, in patients bearing prolactinoma. Also the TRH releasable pool of TSH and PRL in these patients seems to be unaffected by estrogenic treatment.


Ethynilestradiol TSH PRL domperidone TRH tumoral hyperprolactinemia 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Besses G.S., Burrow G.M., Spauling S.W., Donabedian R.K. Dopamine infusion acutely inhibits the TSH and PRL response to TRH. J. Clin. Endocrinol. Metab. 41: 985, 1975.PubMedCrossRefGoogle Scholar
  2. 2.
    Healy D.L., Burger H.G. Increased prolactin and thyrotropin secretion following oral metoclopramide: dose-response relationship. Clin. Endocrinol. (Oxf.) 7: 195, 1977.CrossRefGoogle Scholar
  3. 3.
    Scanlon M.F., Weightman D.R., Mora B., Heath M., Shale D., Snaw M.H. Evidence for dopaminergic control of thyrotropin secretion in man. Lancet 2: 421, 1977.PubMedCrossRefGoogle Scholar
  4. 4.
    Massara F., Camanni F., Belforte L., Vergnano W., Molinatti G.M. Increased thyrotropin secretion induced by sulpiride in man. Clin. Endocrinol. (Oxf.) 9: 419, 1978.CrossRefGoogle Scholar
  5. 5.
    Scanlon M.F., Pourmand M., McGregor A.M., Rodriguez-Arnao M.D., Hall K., Gomez-Pan A., Hall R. Some current aspects of clinical and experimental neuroendocrinology with particular reference to growth hormone, thyrotropin and prolactin. J. Endocrinol. Invest. 2: 307, 1979.PubMedGoogle Scholar
  6. 6.
    Scanlon M.F., Rodriguez-Arnao M.D., McGregor A.M., Weightman D., Lewis H., Cook D.B., Gomez-Pan A., Hall R. Altered dopaminergic regulation of thyrotropin release in patients with prolactinomas: comparison with other tests of hypothalamic-pituitary function. Clin. Endocrinol. (Oxf.) 14: 133, 1981.CrossRefGoogle Scholar
  7. 7.
    Massara F., Ghigo E., Gentile L., Camanni F., Molinatti G.M. Thyrotropin and prolactin response to domperidone in subjects with physiologic or pathologic hyperprolactinemia. In: Molinatti G.M. (Ed.), A clinical problem: Microprolactinoma. Diagnosis and treatment. Excerpta Medica, Amsterdam, 1982, p. 35.Google Scholar
  8. 8.
    Massara F., Camanni F., Martra M., Dolfin G.C., Muller E.E., Molinatti G.M. Reciprocal pattern of the TSH and PRL response to dopamine receptor blockade in women with physiological or pathological hyperprolactinemia. Clin. Endocrinol. (Oxf.) 18: 103, 1983.CrossRefGoogle Scholar
  9. 9.
    Faglia G., Beck-Peccoz P., Ferrari C., Ambrosi B, Spada A, Travaglini P. Enhanced plasma thyrotropin response to TRH following estradiol administration in man. Clin. Endocrinol. (Oxf.) 2: 207, 1973.CrossRefGoogle Scholar
  10. 10.
    Erfurth E.M., Heduer P., Nilsson A. Basal and TRH stimulated serum levels of TSH in patients with hyperprolactinemia and in subjects on estrogen treatment. Acta Endocrinol. (Kbh.) 102: 173, 1983.Google Scholar
  11. 11.
    Smyth P.P.A., Turner J.J., O’Donovan D.K. Effect of stilboestrol therapy on thyrotropin-releasing-hormone (TRH) responsiveness in males. Clin. Endocrinol. (Oxf.) 6: 139, 1977.CrossRefGoogle Scholar
  12. 12.
    Carlson H.E., Jacobs L.S., Daughaday W. Growth hormone, thyrotropin and prolactin responses to TRH following diethylstilboestrol pretreatment. J. Clin. Endocrinol. Metab. 37: 488, 1973.PubMedCrossRefGoogle Scholar
  13. 13.
    Woolf P.D., Gonzales-Barcena D., Schlach D.S., Lee L.A., Auzac J.P., Schally A.V., Kastin A.J. Lack of effect of steroids on TRH mediated thyrotropin release in man. Neuroendocrinology 13: 56, 1973.PubMedCrossRefGoogle Scholar
  14. 14.
    White M.C., Anapiotlan M., Rosenstock J., Mashiter K., Joplin G.F. Heterogeneity of prolactin responses to estradiol benzoate in women with prolactinomas. Lancet 2: 1394, 1981.CrossRefGoogle Scholar
  15. 15.
    Schlechte J., Vangilder J., Sherman B. Predictors of the outcome of transphenoidal surgery for prolactin-secreting pituitary adenomas. J. Clin. Endocrinol. Metab. 52: 785, 1981.PubMedCrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 1984

Authors and Affiliations

  • E. Ghigo
    • 1
  • G. Pogliano
    • 1
  • C. Campagnoli
    • 2
  • A. Bertagna
    • 1
  • F. Camanni
    • 1
  • F. Massara
    • 1
  1. 1.Cattedre di Endocrinologia e di Malattie del Ricambio dell’Università di TorinoTorinoItaly
  2. 2.Ospedale Ostetrico e Ginecologico S. AnnaTorinoItaly

Personalised recommendations